What they were paid
Evommune Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $0 | — | $0 | — | $0 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Evommune, Inc. DEF 14A filed April 21, 2026, accession 0001193125-26-166747, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025Evommune pays directors a $40,000 cash retainer and $440,000 in Options.
Committees
FY2025 · as the proxy prints themScience and Technology
The rest of the Evommune board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Arthur Kirsch | Independent Director | $451,244 |
| Benjamin F. McGraw III, Pharm.D | Chair of the Board | $490,827 |
| David E. Cohen, M.D., M.P.H | Independent Director | $484,577 |
| Eugene A. Bauer, M.D | Director | $0 |
| Felice Verduyn-van Weegen | Independent Director | $0 |
| Luis Peña | Director | $0 |
| Rob Hopfner, R.Ph., Ph.D | Independent Director | $0 |
The full Evommune compensation record
free company briefThis page is one director within Evommune's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat